tbuckley/cabot-search huggingface dataset:
FRI0602 Beliefs about Subcutaneous Biological and Oral Medications in Patients with Rheumatoid Arthritis. Arco Study:
Authors: C. Marras Fernandez-Cid, I. Monteagudo, J. Calvo-Alén, E. Raya Alvarez, T.R. Vázquez-Rodríguez, J.V. Tovar Beltrán, C. Díaz-Miguel Pérez, J.M. Ruiz Martín, R. Cáliz Cáliz, L. Cea-Calvo, S. Fernández, S. Martínez Pardo, G. Salvador Alarcόn
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients9 perception on the usefulness of their medicines is important to implement actions that increment confidence and minimize concerns. <h3>Objectives</h3> To describe the beliefs that patients with rheumatoid arthritis (RA) treated with subcutaneous (SC) biological drugs have on their oral and SC biological medications for RA. <h3>Methods</h3> ARCO is a cross-sectional study in RA patients &gt;18 years-old on SC biological drugs from 42 Spanish hospitals. The beliefs on medication was assessed with the Spanish version of the Beliefs About Medicines Questionnaire (BMQ), obtaining their agreement with each statement through a Liker scale from 1 (strongly disagree) to 5 (strongly agree). The BMQ score was obtained subtracting the "concerns subscale" score from that of the "necessity scale" <h3>Results</h3> 364 patients were included (mean age 54.9 years [SD 12.5]; 77.5% women, median RA duration 7.8 years). The mean scores of the BMQ for the oral and SC biological medication were 5.60 (SD 5.03) and 5.22 (SD 5.43) respectively; the median for both was 5 (p = NS). For the oral medication, 84.4% of the patients scored higher in the necessity subscale than in the concerns subscale, whereas for the SC biological the percentage was 78.3%. Some 73.3% scored necessity &gt; concerns for both drugs, whilst 4.4% scored necessity &lt; concerns for. In the necessity subscale, the highest score for the oral medications was "My health, at present, depends on my medicines" and for SC "My medicines protect me from becoming worse" (table). In the concerns subscale, the highest score was "I sometimes worry about the long-term effects of my medicines" for both groups of drugs (table). <h3>Conclusions</h3> RA patients show strong positive beliefs about the necessity of their medicines for RA, although a substantial percentage also describes concerns. The beliefs are similar for oral and SC biological medicines. Rheumatologists should contribute to improve aspects related to specific patients9 concerns. <h3>Acknowledgement</h3> The ARCO study was funded by Merck Sharp &amp; Dohme Spain. <h3>Disclosure of Interest</h3> None declared
SP0160 Protective and Detrimental Roles of Inflammasomes
Authors: M. Lamkanfi
Journal: Annals of the Rheumatic Diseases (2016)

Inflammasomes are multi-protein platforms that assemble in the cytosol of immune cells to cope with pathogens and cellular stress. The pattern-recognition receptors NLRP1, NLRP3, NLRC4, AIM2 and Pyrin all assemble canonical platforms for caspase-1 activation, and the related inflammatory caspases 4, 5 and 11 respond to cytosolic detection of the Gram-negative lipopolysaccharides. Inflammasomes contributes importantly to controlling pathogen replication through their roles in maturation and secretion of the inflammatory cytokines interleukin-(IL)1β and IL18, and they also induce pyroptosis. Contrasting to their beneficial roles in these host defense responses, deregulated inflammasome activation is thought to be detrimental in the context of chronic inflammatory arthritis and autoinflammatory diseases such as cryopyrin-associated periodic fever syndromes (CAPS) and Familial Mediterranean Fever (FMF). <h3>Disclosure of Interest</h3> None declared
FRI0585 Importance and Level of Implementation of The EULAR/EUMUSC.net Standards of Care for RA in The Netherlands: Similarities and Discordance between Patients and Health Care Professionals
Authors: M. Hifinger, Y. van Eijk, P. Putrik, S. Ramiro, A. Woolf, J. Smolen, M. Stoffer, T. Uhlig, R.H. Moe, M. Saritas, M. van de Laar, H. Vonkeman, M. de Wit, M. Janson, A. van der Helm-van Mil, A. Boonen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> To harmonize care, the core concepts of RA care have been formulated in the 16 EULAR/EUMUSC.net standards of care (SOC). To further empower RA patients and help them to monitor their disease, SOC have been converted into a patient checklist. Yet, the SOC have never been applied to patients and health care professionals (HCP) in a daily practice setting. <h3>Objectives</h3> To assess the importance, level of implementation and implementation gap of the 16 EULAR/EUMUSC.net SOC among patients with RA and HCPs in the Netherlands. <h3>Methods</h3> Dutch patients with RA from two hospitals, rheumatologists as well as nurses of the Dutch Society of Rheumatology completed a questionnaire on the importance and level of implementation (0–10 numeric rating scale (NRS); 10=highest, best) of each SOC. An implementation gap, identifying the SOC with a higher need for implementation, was calculated for all individual SOC: (maximal implementation (10) – reported implementation) X reported importance. Patients completed a NRS on global disease activity. Comparisons across subgroups were analysed with Mann-Whitney test. <h3>Results</h3> Overall, 217 patients and 91 HCPs (52 rheumatologists and 39 nurses) were included. The 3 SOC with the highest importance and implementation scores were similar for patients and HCPs, and showed almost no implementation gap (table). While for both patients and HCPs the implementation gap for alternative therapies was high, it should be noted that its perceived importance was relatively low (patients: 6.5 (3.2) and HCPs 6.2 (2.2)). The remaining important implementation gaps referred to SOC with a low implementation, but a high importance, for both patients and HCPs (table). Within patients, perceived level of implementation of most of the SOC was lower in those with higher disease activity. No important differences were found between subgroups according to gender, age, disease duration, education or health literacy. <h3>Conclusions</h3> In the Netherlands, patients and HCPs share similar opinions on the most important aspects of RA care and agree these SOC are appropriately implemented. However, HCPs identified a need for improvement with regard to early diagnosis and providing a treatment plan to the patient. Patients experienced an unmet need in personalized exercise and access to trustful information. This audit of care using SOC identified areas for improvement for care that should be addressed. <h3>Disclosure of Interest</h3> None declared
Genome-Wide Association Studies of Genetic Incompatibility That Is Relevant to the Development of GvHD in Unrelated Bone Marrow Transplantation
Authors: Seishi Ogawa, Aiko Matsubara, Koichi Kashiwase, Makoto Onizuka, Masashi Sanada, Motohiro Kato, Yasuhito Nannya, Yoshiki Akatsuka, Takakazu Kawase, Masahiro Satake, Junko Takita, Yasuo Morishima, Shigeru Chiba, Hiroo Saji, Hidetoshi Inoko, Yoshihisa Kodera, Takehiko Sasazuki
Journal: Blood (2008)
Mitoferrin1 Transgenic Zebrafish Line Serves as a Model to Study Erythroid Cell Fate during Hematopoiesis
Authors: Julio Amigo, Ming Yu, Camila O. dos Santos, Prasad N. Paradkar, Jeffrey D. Cooney, Jerry Kaplan, Mitchell J. Weiss, Alan B. Cantor, Barry H. Paw
Journal: Blood (2008)
A Preclinical Non-Human Primate Model to Test Reversible Myeloablation Following IV Busulfan Therapy without Stem Cell Rescue
Authors: Nadim Mahmud, Amit Khanal, Simona Taioli, Emre Koca, Sujata Gaitonde, Benjamin Petro, Karen Sweiss, Damiano Rondelli
Journal: Blood (2015)
PTH-068 Same Lab, Same Faeces, Different Methods and Some Different Calprotectin Results
Authors: KN Lythgoe, SJ McCann
Journal: Gut (2016)

<h3>Introduction</h3> Faecal calprotectin (FC) has recently become widely used to differentiate between IBS and IBD following NICE diagnostic guidelines (DG11). There are a number of different assays in use throughout the UK using different extraction methods. We have evaluated a newly introduced Quanta-Lite FC assay (Werfen Ltd, UK) with Eurospital (ES) extraction tubes and compared it to our routine Buhlmann assay with Calex extraction tubes. <h3>Methods</h3> All samples were received &lt;72 hrs from collection and frozen upon receipt. The samples, a mixture of both primary and secondary care requests, were thawed at 2–8<sup>o</sup>C overnight then equilibrated to room temperature for 60 minutes before extraction. The same 76 faecal samples were extracted initially using the Bühlmann Calex tubes and then the ES extraction tubes. FC was then measured using the different ELISA methods on the DS2 ELISA platform. <h3>Results</h3> The Calex and ES extraction tubes use 10 and 60 µg/µl of faecal sample respectively. After sampling homogenisation and centrifugation is only required with the Calex tubes whereas the ES tubes require a further step of 20 minutes on the roller mixer. Calex tubes can be loaded directly on the DS2 analyser, whereas the ES tubes require transfer of the supernatant to a secondary tube. The equation of correlation was Buhlmann =0.27 Werfen + 6.6, r<sup>2</sup> = 0.813 hence the Buhlmann assay results are on average 3.0 times higher than the Werfen assay. At present within our laboratory Buhlmann results of &gt;49 ug/g are categorised as abnormal (A) and a referral to Gastroenterology is suggested. The Werfen assay reports results of &lt;50 ug/g as normal (N), 50–120 ug/g as borderline (B) with re-testing in 4–6 weeks suggested and &gt;120 ug/g as A. The Buhlmann method states an elevated level of between 50–200µg/g may represent mild disease. The assays categorised the 76 samples as follows: Buhlmann, N 40.8% and A 59.2% and Werfen N 61.8%, B 19.7%, A 18.4%. With the current interpretation 59% of the samples analysed by the Buhlmann method were abnormal whereas 18% of samples tested with the Werfen kit were deemed abnormal. In order to have better interpretative agreement between the assays a borderline range with the Buhlmann assay should be 159 ug/g to 415 ug/g and positive &gt;415 ug/g. <h3>Conclusion</h3> In conclusion the Calex tubes are easier to use than the ES tubes: they utilise a smaller sample size; requires less pre-analytical steps; and do not require an additional sample transfer which often resulted in splashing of the extracted faeces. The assays had poor overall diagnostic agreement for the samples tested. Different cut-offs should be used for each assay in order to have a comparable interpretation. Each assay should be assessed in relation to clinical outcome prior to use. We also recommend that the FC method used is reported with the result. <h3>Disclosure of Interest</h3> None Declared
Gene Expression Profiles for Normal Human Bone Marrow-Derived CD34+ Stem Cells and CD34−/CD33+ Myeloid-Committed Progenitor Cells in Response to Daily Granulocyte-Colony-Stimulating Factor (G-CSF) Treatment.
Authors: Andrew A.G. Aprikyan, David Pritchard, Conrad W. Liles, Steve Schwartz, David C. Dale
Journal: Blood (2004)
SP0021 Free Radical Signaling behind The Muscle Weakness Associated with Rheumatoid Arthritis
Authors: J. Lanner
Journal: Annals of the Rheumatic Diseases (2016)

In addition to the primary symptoms arising from inflammatory processes in the joints, muscle weakness and impaired work capacity are commonly reported by patients with rheumatoid arthritis (RA). Reduced muscle strength has always been more or less synonymous with decreased muscle mass. However, our data show that muscle weakness associated with RA is not only a result of atrophic muscles. Instead, intracellular (intrinsic) muscle dysfunction appears as important factors behind arthritis-induced muscle weakness. Our data suggests that the impaired capacity to produce force is the result of free radical (reactive oxygen/nitrogen species (ROS/RNS)) signaling altering the intracellular Ca2+ release and contractile proteins (myosin and actin) inside the skeletal muscle fibers. Here our latest data on the mechanisms behind arthritis-induced skeletal muscle weakness from animal studies and patients with RA will be presented. Altered contractile function induced by the RNS peroxynitrite (ONOO-) and the prospective of using antioxidant treatment to counteract muscle weakness in inflammatory conditions will be discussed. <h3>Disclosure of Interest</h3> None declared
Irradiation Sterilized Gelatin–Water–Glycerol Ternary Gel as an Injectable Carrier for Bone Tissue Engineering
Authors: Yantao Zhao, Liwei Han, Jun Yan, Zhonghai Li, Fuli Wang, Yang Xia, Shuxun Hou, Hongbin Zhong, Feimin Zhang, Ning Gu
Journal: Advanced Healthcare Materials (2016)

Injectable gelatin gels offer an attractive option for filling bone defects. The challenge is to fabricate gelatin gels with optimal gelation properties, which can be irradiation sterilized. Here, a gelatin–water–glycerol (GWG) gel is reported for use as a broad‐spectrum injectable carrier. This ternary gel is high in glycerol and low in water, and remains stable after gamma irradiation at doses (25 kGy). As an injectable gel, it remains a viscous solution at gelatin concentrations ≤2.0%, at room temperature. Its storage modulus increases dramatically and eventually exceeds the loss modulus around 46–50 °C, indicating a transition from a liquid‐like state to an elastic gel‐like state. This ternary gel ranges significantly in terms of storage modulus (12–1700 Pa) while demonstrating a narrow pH range (5.58–5.66), depending on the gelatin concentration. Therefore, it can be loaded with a variety of materials. It is highly cytocompatible compared with saline in vivo and culture media in vitro. When loaded with demineralized bone matrix, the composites show favorable injectability, and excellent osteogenesis performance, after irradiation. These features can be attributed to high hydrophilicity and fast degradability. These findings justify that this ternary gel is promising as an irradiation‐sterilized and universal injectable delivery system.
Evaluating Prolonged Gvhd Based On Monocyte and T-Cell Activation, Leads to Early Detection of Immunological Changes Before Gvhd Exacerbations
Authors: Rie Kuroda, Toshihiro Fujiki, Shintaro Mase, Raita Araki, Hideaki Maeba, Shoichi Koizumi, Akihiro Yachie, Ryosei Nishimura
Journal: Blood (2012)
Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in liver fatty acid binding protein null mice
Authors: Elizabeth P. Newberry, Yan Xie, Susan M. Kennedy, Mark J. Graham, Rosanne M. Crooke, Hui Jiang, Anping Chen, Daniel S. Ory, Nicholas O. Davidson
Journal: Hepatology (2016)

Blocking hepatic very low‐density lipoprotein secretion through genetic or pharmacologic inhibition of microsomal triglyceride transfer protein (Mttp) causes hepatic steatosis, yet the risks for developing hepatic fibrosis are poorly understood. We report that liver‐specific Mttp knockout mice (Mttp‐LKO) exhibit both steatosis and fibrosis, which is exacerbated by a high‐transfat/fructose diet. When crossed into germline liver fatty acid (FA) binding protein null mice (Mttp‐LKO, i.e., double knockout mice) hepatic steatosis was greatly diminished and fibrosis prevented, on both low‐fat and high‐fat diets. The mechanisms underlying protection include reduced long chain FA uptake, shifts in FA distribution (lipidomic profiling), and metabolic turnover, specifically decreased hepatic 18:2 FA and triglyceride species and a shift in 18:2 FA use for oxidation versus incorporation into newly synthesized triglyceride. Double knockout mice were protected against fasting‐induced hepatic steatosis (a model of enhanced exogenous FA delivery) yet developed steatosis upon induction of hepatic de novo lipogenesis with fructose feeding. Mttp‐LKO mice, on either the liver FA binding protein null or Apobec‐1 null background (i.e., apolipoprotein B100 only) exhibited only subtle increases in endoplasmic reticulum stress, suggesting that an altered unfolded protein response is unlikely to account for the attenuated phenotype in double knockout mice. Acute, antisense‐mediated liver FA binding protein knockdown in Mttp‐LKO mice also reduced FA uptake, increased oxidation versus incorporation of 18:2 species with complete reversal of hepatic steatosis, increased hepatic injury, and worsened fibrosis. Conclusion: Perturbing exogenous hepatic FA use modulates both hepatic steatosis and fibrosis in the setting of hepatic Mttp deletion, adding new insight into the pathophysiological mechanisms and consequences of defective very low‐density lipoprotein secretion. (H epatology 2017;65:836‐852).
The Role of Physicians in Preventing Firearm Suicides
Authors: Chana A. Sacks
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
SAT0194 IL-6 Serum Levels and Coronary Microvascular Dysfunction in Patients with Systemic Sclerosis
Authors: E. Pigatto, G. Famoso, A. Scanu, P. Polito, P. Galozzi, E. Zanatta, L. Punzi, F. Cozzi, F. Tona
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Functional impairment of coronary microcirculation is thought to be a pathway in the development of cardiac involvement in systemic sclerosis (SSc). The underlying mechanism is not fully understood. A reduction of coronary flow reserve (CFR) suggests a coronary microvascular dysfunction (CMD) and predicts adverse outcomes in several cardiovascular diseases. Interleukin-6 (IL-6) is involved in the pathogenesis of SSc and it is a marker of immune activation. High serum levels of IL-6 are correlated with the severity of skin lesions, pulmonary fibrosis and pulmonary hypertension, but the role of IL-6 in the development of cardiomyopathy in SSc is yet not clear. <h3>Objectives</h3> To assess the relationship between CFR values and IL-6 serum levels in SSc. <h3>Methods</h3> Forty SSc patients (32 female and 8 male, aged 55±11 years), classified according to the 2013 ACR/EULAR criteria, were enrolled. Disease activity was evaluated by EUSTAR score. Twenty-three patients were affected by diffuse cutaneous form and 17 by limited form. All patients had no clinical evidence of heart disease. Coronary flow velocity in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography at rest and during adenosine infusion. CFR was the ratio of hyperaemic diastolic flow velocity (DFV) to resting DFV. A CFR ≤2.5 was considered abnormal and marker of CMD. Serum levels of IL-6 and of cardiac biomarkers (pro-BNP and troponin I) were evaluated in all patients. <h3>Results</h3> CFR was reduced in 21 patients (52.5%). The average value was 2.08±0.29. Serum levels of IL-6 (n.v. &lt;2.5 pg/mL), pro-BNP (n.v. &lt;125 ng/L) and troponin I (n.v. &lt;0.0017 μg/L) were increased respectively in 50%, 45% and 27.5% of cases. No significant correlation between CFR and subsets of SSc was found. Higher EUSTAR score were correlated with reduced CFR (<i>p=0.037</i>) and high values of IL-6 (<i>p=0.002</i>). A significant correlation between the increase levels of IL-6 and the reduction of CFR (<i>p=0.039</i>) was found. <h3>Conclusions</h3> Our results showed that high serum levels of IL-6 are associated with CMD independently from the severity of SSc. A positive correlation between IL-6, EUSTAR score and the impairment of CFR in SSc patients may be suggest an implication of IL-6 in the cardiac pathogenesis of SSc. The evaluation of serum IL-6 might represent a tool for the prediction of CMD, suggesting a role in the increased cardiovascular risk in patients with SSc. Moreover they could open new possibilities for the treatment of SSc cardiomyopathy. <h3>Disclosure of Interest</h3> None declared
Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy
Authors: Heather Landau, Hani Hassoun, Michael A. Rosenzweig, Christina Bello, Elizabeth Hoover, Elyn Riedel, Alex Lesokhin, Nikoletta Lendvai, Adam Cohen, Stephen Nimer, Raymond L. Comenzo
Journal: Blood (2010)
Flexible Antigen-Specific Redirection of Human Regulatory T Cells Via a Novel Universal Chimeric Antigen Receptor System
Authors: Stefanie Koristka, Marc Cartellieri, Anja Feldmann, Claudia Arndt, Simon Loff, Irene Michalk, Roberta Aliperta, Malte von Bonin, Martin Bornhäuser, Armin Ehninger, Gerhard Ehninger, Michael P. Bachmann
Journal: Blood (2014)
ATCT-10HIGH-DOSE CYTARABINE SALVAGE THERAPY FOR RECURRENT PRIMARY CNS LYMPHOMA
Authors: Marc Chamberlain
Journal: Neuro-Oncology (2015)

BACKGROUND: Treatment of recurrent primary CNS lymphoma (PCNSL) though not standardized most often utilizes whole brain radiotherapy, re-challenge with high-dose methotrexate, or administration of an alkylating chemotherapy. High-dose cytarabine (HD-araC) has been advocated as an active agent in PCNSL but limited information exists regarding single agent activity in the recurrent setting. PATIENTS AND METHODS: A retrospective review of 14 patients (10 males, 4 females: median age 60 years) with recurrent PCNSL treated at second recurrence with single agent HD-araC. HD-araC was administered at 2gm/m2 over a 3-hour infusion every 12 hours for a total of 4 doses (defined as a cycle of therapy). GM-CSF was administered at conclusion of HD-araC. Patients were clinically and radiographically evaluated every 4-weeks. RESULTS: Common toxicity criteria Grade 3 or 4 toxicity included thrombocytopenia (11 patients; 79%), anemia (10; 71%), fatigue (8; 57%), mucositis (8; 57%), neutropenia (8; 57%) and neutropenic fever (5; 36%). No patient discontinued therapy due to toxicity nor were there any treatment-related deaths. Best response to HD-araC was stable disease in 6 patients (43%), partial response in 5 (36%) and progressive disease in 3 (21%). Median progression free survival 3 months (range 2-5 months; 95% CI 2-4 months) and progression free survival was 0% at 6-months. Median survival after onset of HD-araC was 12 months (range 3-18+ months; 95% CI 3-15 months). CONCLUSIONS: Single agent HD-araC has limited activity in recurrent PCNSL and is associated with significant toxicity in this small retrospective study.
Evidence That Human Very Small Embryonic-Like Stem Cells (VSELs) Are Mobilized by G-CSF Into Peripheral Blood: A Novel Strategy to Obtain Human Pluripotent Stem Cells for Regenerative Medicine.
Authors: Satish Medicetty, Mariusz Z Ratajczak, Magdalena J Kucia, Ewa K. Zuba-Surma, Izabela Klich, Wayne A Marasco, Denis O. Rodgerson
Journal: Blood (2009)
Reconstitution of NK Cells after Haploidentical Hematopoietic Transplants: Immaturity of NK Cells and Inhibitory Effect of NKG2A Override GvL Effect Expected by Alloreactive NK Cells.
Authors: Stephanie Nguyen, Nathalie Dhedin, Jean-Paul Vernant, Mathieu Kuentz, Sophie Hilpert, Nathalie Rouas Freiss, Ahmad Al Jijakli, Patrice Debre, Vincent Vieillard
Journal: Blood (2004)